| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Entrepreneurialism > Entrepreneurial Inertia |
|
E-Folder - Entrepreneurial Inertia
From the moment a business is launched, a phenomenon begins to take over. The ant According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product i-entrepreneurial inertia begins to set in. Every business starts out entreprene ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in urial. Hungry and eager, innovative, open-minded and resourceful, all of its atte lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. tion focused on finding and keeping customers. Things start to happen and the bu here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe siness begins to grow. Meanwhile, something sinister begins to occur. Slowly, su d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro tly and insidiously, the anti-entrepreneurial inertia begins to creep in. As the ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc business continues to grow, we take on more and more responsibility. We hire oth easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi er people, who now need to be managed. We establish policies and procedures, rout nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically nes, and rituals as part of our success strategy. Our focus has begun to shift. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ Without realizing it, we’ve grown a little less curious, a little less open-minde ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi and a little less attentive to the needs of our customers. Soon we become “expe ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a rts” in our field. We’ve achieved success. We know all there is to know about our dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod particular field of endeavor. We’ve established an identity or a culture within cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ur organization. Without realizing it, we’ve lost our entrepreneurial zeal. We’v tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen e grown less open minded, now focused on protecting what we have rather than scou t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ing the horizon, looking for what we don’t. We stop listening. We stop learning. ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust We ignore or deny the changes that are occurring all around us. (Think Maxwell H y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ouse vs. Starbucks) Without realizing it we’ve moved to the other end of the spe . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de trum. Without realizing it we’ve become complacent. Without realizing it we’ve c elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip reated an opportunity for the next eager and innovative, open-minded entrepreneur tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How to Improve Your Low Credit Rate
|